Liver cancer incidence lower in patients with nonalcoholic fatty liver disease than hepatitis C

	Tweet

Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or Cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C virus (HCV), according to the prospective study published in the October issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. Patients with both NAFLD and HCV had similar mortality rates.

NAFLD has become the most prevalent cause of chronic liver disease worldwide, with studies reporting up to 30% of the general population and 75% of obese individuals having the disease. A minority of cases develop fibrosis or Cirrhosis of the liver, and NAFLD with advanced fibrosis or Cirrhosis can lead to hepatic-related complications, HCC, liver failure or death. While the incidence of NAFLD has increased, studies of the natural history of the disease in conjunction with advanced fibrosis or Cirrhosis and later outcomes have been limited.

“Our study reports on the long-term morbidity and mortality of NAFLD patients with advanced fibrosis or Cirrhosis by prospectively following up cases from four international collaborating hepatology centers,” explains lead author Dr. Neeraj Bhala from the University of Oxford in the UK. “Understanding the long term prognosis of NAFLD patients compared with patients affected by other liver diseases such as chronic HCV was an important aspect of our study.” Medical evidence suggests that while HCV is currently the leading indication for liver transplantation, affecting more than 5 million individuals in the U.S, HCV incidence has plateaued, while that for NAFLD is on the rise. 

In the largest prospective study of participants with advanced fibrosis or Cirrhosis to date, the team recruited 247 patients with NAFLD and 264 patients with HCV infection who were not previously treated or were unresponsive to therapy from centers in Australia, Italy, the UK and the USA. Patients in both groups were Child-Pugh class A and had advanced fibrosis (stage 3) or Cirrhosis (stage 4) confirmed by liver biopsy at the onset of the study. Follow-up in the NAFLD and HCV groups was a mean of 86 and 75 months, respectively.

Of those patients in the NAFLD group, 19% had liver-related complications and 13% died (or received transplants). Liver-related complications and deaths (or transplants) in the HCV cohort were lower at 17% and 9%, respectively. However, after adjusting for age and gender, the incidence of liver-related complications, including liver cancer, was lower in the NAFLD group compared to the HCV cohort. Researchers found that cardiovascular complications and overall mortality were comparable between the groups, although moderate differences cannot be excluded, highlighting the need for even larger collaborative prospective studies.

In a related editorial published this month in Hepatology, Dr. Mary Rinella with Northwestern University Medical School in Chicago, Illinois said, “The study by Bhala and colleagues expands our knowledge of the natural history of NAFLD and NASH. While HCC was not surprisingly higher in untreated patients with HCV compared to NAFLD, this study highlights the potential of HCC development in non-cirrhotic patients with HCV and NASH. If patients with NAFLD or HCV are likely to develop HCC before the development of Cirrhosis, this has tremendous implications for how and when liver cancer screening should begin in patients with liver disease.”

###

Contact: Dawn Peters

781-388-8408
Wiley-Blackwell

RELATED STORIES:
Scientists identify specific markers that trigger aggressiveness of liver cancer   New Technique in Treating Patients With Liver Cancer Proves Effective   Metformin May Protect Against Liver Cancer   Liver cancer is likely caused by cycles of liver cell death and renewal   A promising molecular target for liver cancer therapy   Wilmot Researchers Create New Way to Study Liver Cancer   Blacks with Liver Cancer More Likely to Die   Racial disparities evident in early-stage liver cancer survival   Liver transplant recipients almost 3 times more likely to develop cancer   Proton beams control liver tumors   Researchers Identify Gene Linked to Aggressive Progression of Liver Cancer   New study confirms link between nonalcoholic steatohepatitis and liver cancer   More evidence coffee may cut risk of liver cancer   Studies of patients with cirrhosis uncover limitations in liver cancer screening   A diagnostic marker in hepatocellular carcinoma   Cycles of Cell Death, Proliferation Key to Liver Cancer   Liver cancer patients less likely to die on wait list than candidates without carcinomas   The ignored virus that causes liver cancer   Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation   Type of Anesthesia May Affect Recurrence Risk after Liver Cancer Procedure   Omega-3 fatty acids inhibit the growth of liver cancer cells   How to differentiate benign from malignant bile duct strictures?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]